Evaluation of whole sporozoite vaccines for...

In the News

Ifakara scientist explains why ending Tuberculosis requires better diagnostics

Ending tuberculosis through better diagnostics Author: Dr. Frederick Haraka, MD Yes, to end tuberculosis (TB), we need better diagnostic tools! TB is among the deadliest diseases in the world. In …

Study: 12% of people living with HIV in rural Tanzania have hypertension

Dar es Salaam, Tanzania (March 9, 2017). IHI Research Scientist Dr Kim Mwamelo presents findings of the study in Boston, US, last year at the Conference on Retroviruses and Opportunistic …

Recent Projects

Assessing the progress towards rabies elimination from Pemba Island, Tanzania

Rabies is a deadly disease endemic in dog populations across Africa. Although rabies can be eliminated through mass dog vaccination, there has been little investment in dog vaccination in Africa …

Engaging pastoralists in controlling malaria mosquitoes in their communities

The project is aimed at applying pastoralists’ knowledge to find water bodies during the dry season and accurately identify aquatic habitats that can be treated with larvicide pyriproxyfen (PPF) to …

Evaluation of whole sporozoite vaccines for malaria elimination

This program of work is led by a clinical team at the Ifakara Health Institute Clinical Trial Facility at Kingani, Bagamoyo (IHI – CTF) which is conducting a series of studies to evaluate the potential impact of whole sporozoite malaria vaccine candidates to prevent malaria infection and thereby block transmission with the goal of achieving malaria elimination in Sub-Sahara Africa. The work is conducted in two countries; Tanzania and Equatorial Guinea. Studies and major contributions of the work to date include:

dr-omar-in-the-labBSPZC1 (NCT01540903): The first Controlled Human Malaria Infection (CHMI) study using purified fully infectious malaria sporozoites in an African country was conducted at IHI-CTF at Kingani, Bagamoyo in 2012. This trial demonstrated the safety and infectivity of the fully infectious purified sporozoites (PfSPZ Challenge) leading to the establishment of the CHMI model for testing new malaria vaccines and drugs in Africa

BSPZV1 (NCT02132299): Study conducted in IHI-CTF at Kingani, Bagamoyo between 2014-2015. This was the first PfSPZ Vaccine (radiation attenuated sporozoites) trial to be conducted in Africa. The trial established a very good safety and tolerability profile for the PfSPZ vaccine and was the basis for further studies in Mali and Equatorial Guinea.

BSPZV2 (NCT02613520): Study conducted in IHI-CTF at Kingani, Bagamoyo between 2015- 2016. Worldwide, this was the first PfSPZ Vaccine (radiation attenuated sporozoites) trial in adolescents and children. The trial established a very good safety and tolerability profile for PFSPZ vaccine in younger age groups and well as better immune responses in younger children. This work was the basis for further studies in Equatorial Guinea, Kenya and other African countries.

Partners

Swiss Tropical and Public Health Institute
Sanaria Inc.

Funders

The government of Equitorial Guinea, Marathon Oil, Noble Energy and AMPCO
Medicines for Malaria Ventures (MMV)

Projects Location

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016